Looking Ahead in Renal Cell Carcinoma: Integrating New Agents in the Armamentarium of the Urologist

European Urology, Supplements

Volumn 6, Issue 7, 2007, Pages 505-509

  Patard, Jean Jacques ^a  

^a RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Clinical practice; Renal cell carcinoma; Targeted therapies; Urologist

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CYTOKINE; INTERLEUKIN 2; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ALOPECIA; CANCER ADJUVANT THERAPY; CANCER SURGERY; CLINICAL PATHWAY; CLINICAL PRACTICE; CLINICAL TRIAL; DESQUAMATION; DIARRHEA; DISEASE MARKER; DRUG EFFICACY; DRUG ERUPTION; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MEDICAL SPECIALIST; METASTASIS; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; REVIEW; SYSTEMIC THERAPY;

EID: 33846849394     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2007.01.013     Document Type: Review

References (23)

1. National Comprehensive Guidelines Network. Available at: http://www.nccn.org. Accessed 21 July 2006.
2. Lam J.S., Shvarts O., and Pantuck A.J. Changing concepts in the surgical management of renal cell carcinoma. Eur Urol 45 (2004) 692-705
3. Lam J.S., Shvarts O., Leppert J.T., et al. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 173 (2005) 1853-1862
4. Mulders P.F., and De Mulder P.H. The role of adjuvant immunotherapy in renal cell carcinoma. Curr Urol Rep 3 (2002) 44-49
5. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer [database online]. Cochrane Database Syst Rev 2005;CD001425.
6. McDermott D.F., Regan M.M., Clark J.I., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133-141
7. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21 (2003) 3127-3132
8. Motzer R.J., Bacik J., Murphy B.A., et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289-296
9. Negrier S., Perol D., Ravaud A., et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. J Clin Oncol 23 Suppl (2005) 380s (abstract no. 4511)
10. Motzer R.J., and Bukowski R.M. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 5601-5608
11. Dhanda R., Gondek K., Song J., et al. A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo. J Clin Oncol 24 Suppl (2006) 225s (abstract no. 4534)
12. Eisen T., Bukowski R.M., Staehler M., et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival. J Clin Oncol 24 Suppl (2006) 223s (abstract no. 4524)
13. Escudier B. Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. Eur J Cancer Suppl 3 (2005) 226 (abstract no. 794)
14. McKillop C. Interview with professor Per-Anders Abrahamson: angiogenesis and renal cell carcinoma. Eur Urol 50 (2006) 609-611
15. Patard J.-J., Rioux-Leclercq N., and Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 49 (2006) 633-643
16. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655-1659
17. Mickisch G.H., Garin A., van Poppel H., et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358 (2001) 966-970
18. Rodriguez A., and Sexton W.J. Management of locally advanced renal cell carcinoma. Cancer Control 13 (2006) 199-210
19. Atkins M., Regan M., McDermott D., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11 (2005) 3714-3721
20. Bui M.H., Seligson D., Han K.R., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9 (2003) 802-811
21. Jacobsen J., Grankvist K., Rasmuson T., et al. Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma. BJU Int 97 (2006) 1102-1108
22. Lam J.S., Leppert J.T., Yu H., et al. Expression of the vascular endothelial growth factor family in tumor dissemination and disease free survival in clear cell renal cell carcinoma. J Clin Oncol 23 Suppl (2005) 387s (abstract no. 4538)
23. Leppert J.T., Lam J.S., Yu H., et al. Targeting the vascular endothelial growth factor pathway in renal cell carcinoma: a tissue array based analysis. J Clin Oncol 23 Suppl (2005) 386s (abstract no. 4536)